Compare Novo Nordisk A/S (NVO) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Novo Nordisk A/S trades at $38.6 (market cap $165.31B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.16 (market cap $3.80B). The key difference: Novo Nordisk A/S is far larger — about 43.5× Vanguard Global ex-US Real Estate Index Fd ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days on average.
| NVO | VNQI | |
|---|---|---|
Market Cap | $165.31B | $3.80B |
Volume | 11,432,838 | 277,049 |
Sector | Health | — |
52-Week High | $63.98 | $50.76 |
52-Week Low | $35.29 | $41.81 |
Typical Hold Time | 116 Days | 95 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
VNQI trades at $42.15, up 0.81% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF focuses on international real estate, offering diversification and a higher dividend yield than some peers, but key financial ratios are not disclosed in the provided data. Recent news highlights a significant drop in short interest and comparisons with competing real estate ETFs.
The outlook remains cautious due to weak technical momentum and global real estate market uncertainties. Opportunities include international diversification and income from dividends, but risks involve currency fluctuations, economic cycles abroad, and underperformance versus U.S. real estate. Investors should weigh the bearish technicals against long-term diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
